J9313Drugs Administered Other than Oral Method
Injection, moxetumomab pasudotox-tdfk, 0.01 mg
Short description: Inj., lumoxiti, 0.01 mg
- Effective date
- October 1, 2019
- Termination date
- —
Related codes (J-series)
J0013Esketamine, nasal sprayJ0014Cocaine hcl nasal (goprelto)J0120Tetracyclin injectionJ0121Inj., omadacycline, 1 mgJ0122Inj., eravacycline, 1 mgJ0129Abatacept injectionJ0130Abciximab injectionJ0131Inj, acetaminophen (nos)J0132Acetylcysteine injectionJ0133Acyclovir injectionJ0134Inj acetaminophen -freseniusJ0135Adalimumab injection
Frequently asked questions
What is HCPCS code J9313?
J9313 is a HCPCS Level II code for Injection, moxetumomab pasudotox-tdfk, 0.01 mg.
What category is HCPCS code J9313 in?
J9313 falls under the Drugs Administered Other than Oral Method category of HCPCS Level II.
When did HCPCS code J9313 become effective?
J9313 has been effective since October 1, 2019, per CMS's quarterly HCPCS update.
HCPCS Level II data from CMS (public domain). HCPCS Level I (CPT) codes are not included — CPT is copyrighted by the American Medical Association. Always verify codes with authoritative sources before making coding or billing decisions.